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Abstract
The burden of cancer is climbing in all of Africa, yet the continent’s healthcare and political systems have not
prioritized cancer control and treatment-care. Sub-Saharan Africa is predicted to have a greater than 85% increase
in the burden of cancer by 2030. However, African communities have little or no knowledge of cancer. As a result,
many patients present with advanced disease at first consultation leading to poor outcomes. A focused approach
needs to be adopted to address this growing public health threat. Robust engagement by patients and persons
affected by cancer is needed to exert pressure on key public healthcare influencers especially, clinicians,
researchers, political leaders and public health policy-makers to prioritize the disease and to ease the massive
human suffering caused by cancer morbidities and mortalities.
Introduction
Involving well-trained patient advocates in setting the
research and overall cancer control agendas has been
proven beneficial in countries such as the United States
in improving the quality of care people with cancer
receive. In addition, the involvement of patient advo-
cates ensures that financial and other resources are
spent where they are mostly needed rather than on stu-
dies or programs that are of academic interest but of lit-
tle value in furthering medical understanding of the
causes of cancer. It is imperative that research funds are
spent on studies, which will lead to the development of
preventative vaccines and treatments to eradicate cancer.
Understanding patient advocacy
Patient advocacy is an area of lay specialization in health-
care concerned with patient education about health
(rights) and how to obtain needed cancer treatment and
control. Patient advocates provide the healthcare knowl-
edge to the public at large and mainly offer their services
on a non-profit basis. More broadly, patient advocacy can
include groups that develop policies and legislation to
improve systems or processes for patients [1]. Patient
advocates can also be non-patients from disciplines like
social-work or health insurance employed to assist patients
unravel health plans and or to chaperone them through
healthcare systems [1]. It is worth noting that working
within the for-profit sector as a patient advocate may cre-
ate a conflict of interest for an advocate as it makes it hard
for them to protect patients’ interests within a sector that
they are employed.
The discipline of patient advocacy is well-established in
countries like the United States and the United Kingdom,
where non-profit organizations (NGOs) are recognized as
key healthcare partners with clinicians, healthcare policy-
makers, political leaders and researchers. However, patient
advocacy is still in its infancy in most African countries,
especially in the area of cancer advocacy.
African healthcare practitioners and policy-makers still
tend to practice paternalistic medicine, with little mean-
ingful patient participation in treatment decision-making.
Low literacy levels, lack of easy access to the internet,
patriarchy and gender inequity in most African commu-
nities are responsible for the continuation of these
unequal relations between physicians, policy makers and
patients. A new paradigm of patient inclusion in all key
healthcare decisions has to be created and a strong
patient advocacy movement will be critical in ushering in
a more egalitarian healthcare approach in Africa.
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Understanding political advocacy
Political advocacy is a process by an individual or group
which aims to influence public policy and resource allo-
cation decisions within political, economic, and social
systems and institutions. Advocacy can include many
activities that a person or organization undertakes
including media campaigns, public speaking, commis-
sioning and publishing research. Lobbying (often by
interest groups like people with cancer) is a form of
advocacy where a direct approach is made to legislators
on an issue which plays a significant role in modern pol-
itics – for example access to equitable and evidence
based healthcare for all citizens [1].
The rising burden of cancer in Africa: Lessons
from HIV/AIDS
Sub-Saharan Africa has a disproportionate burden of
disease and faces a major public-health challenge from
both communicable and non-communicable diseases
[2]. The World Health Organization (WHO) estimates
that about 551,200 cases of cancer were diagnosed in
sub-Saharan Africa in 2008, with about 421,000 deaths
[2]. Competing burden of disease from health issues
such as tuberculosis, malaria and HIV/AIDS adversely
impact the attention given to cancer at both political
and public healthcare planning levels by African coun-
tries [2]. Sparse oncology equipment and infrastructure,
poor supply of essential drugs, scarcity of qualified
oncology specialists, inadequate hospital palliation and
home based care services and poor cancer registries are
the norm in most African countries to the detriment of
patient care. The current lack of decisive political
responses to cancer control care in Africa has echoes of
a similar lack of focus initially accorded the HIV/AIDS
pandemic by governments on the continent in the
1990s. Patients suffered and hundreds of thousands of
lives were reported to have been lost as African leaders
engaged in a non-scientific debate on whether HIV
caused AIDS, refuting affirmative scientific evidence.
The case of South Africa and HIV/AIDS: Africa and
the global community were astonished when South
Africa’s President Thabo Mbeki accused the West of
impugning Africans’ sexual mores by suggesting that
there was a scientifically proven causal sexual link
between the human immune-deficiency virus and
AIDS. Mbeki noted, “Convinced that (Africans) are
but natural born, promiscuous carriers of germs,
unique in the world, they (scientists) proclaim that
our continent is doomed to an inevitable mortal end
because of our unconquerable devotion to sin and
lust.” [3]. In a study published in 2008, Harvard pub-
lic health researchers argued that the “South African
president’s refusal to accept medical evidence of the
virus was a major obstacle to providing medicine to
patients who desperately needed it.” [4]. The authors
asserted that “Mbeki fought against scientific consen-
sus that AIDS was caused by a viral infection that
could be fought – though not cured – by sophisticated
and expensive drugs.” [4]. It is estimated that more
than 330,000 people died unnecessarily in South
Africa over the period and that 35,000 HIV-infected
babies were born that could have been protected from
the virus and would probably have a limited life [4].
This lack of decisive South African government action
in the face of immense human suffering and unneces-
sary loss of lives led to huge civil society outrage. AIDS
activists from a previously little known non-profit
group called the Treatment Action Campaign (TAC),
assisted by the AIDS Law Clinic from the University of
the Witwatersrand’s Centre for Applied Legal Studies
(CALS), stepped into the breach and forced the gov-
ernment to honor the legal duty of care – owed to
South African citizens living with HIV/AIDS. Political
advocacy by the TAC garnered much international
support for the cause. Under international pressure,
South Africa eventually launched a national program
for the prevention of mother-to-child-transmission in
August 2003 and a national adult treatment program
in 2004 [4]. The TAC’s lobby efforts were also directed
against pharmaceutical multinational companies
whose high drug prices and strangulate drug patents
made access to life-saving medicines for patients diffi-
cult, especially the poor. “Expensive antiretrovirals
(ARVs) came down in price dramatically as a result
of activists’ (political advocates’) campaigning and
public pressure.” [4].
South Africa’s national HIV/AIDS treatment-care
landscape has changed dramatically since 2004 through
the action of TAC. On December 1, 2011 (World AIDS
Day), President Jacob Zuma announced a plan to fight
against HIV/AIDS. The advocacy of the TAC in the
1990s to the mid-2000s chartered and eased the path
for effective collaboration between government and
HIV/AIDS patient groups. Great progress has been
attained in how key HIV/AIDS healthcare policies are
developed and implemented in South Africa. Govern-
ment and healthcare policymakers now appreciate the
value of civil society engagement as key stakeholders in
healthcare planning and implementation.
Cancer advocates and lobby groups would do well to
take critical lessons from their HIV/AIDS counterparts
and find strategies to engage the government in similar
interactions to facilitate the development of a focused, sus-
tainable and scalable National Strategic Plan for Cancer
grounded in evidence based research. Bruising battles have
been fought and won at grave human cost and there is no
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need to repeat painful mistakes – and to cause similar
unnecessary deaths and suffering for cancer patients and
their families. For example, the comprehensive multi-
disciplinary and multi-sectoral HIV/AIDS approach, intro-
duced by President Zuma in South Africa, presents a
prime opportunity for partnerships between national HIV/
AIDS and cancer political advocates. The two diseases
sometimes occur as co-morbidities in the same patient
and it would therefore be highly cost effective to develop
and implement integrated research and treatment plans.
Sufficient research exists on the high incidence of AIDS
defining carcinomas, like Kaposi sarcoma, which is one of
the four common cancers in both men and women in
sub-Saharan Africa. There are also biological connections
between HIV/AIDS and tuberculosis, cervical and breast
cancers among African patients. A strategic approach to
cancer control (factoring these listed diseases) in sub-
Saharan Africa is needed to build on what works and what
is unique to the region.
How science educated patient advocates can
drive cancer advocacy and influence research and
political agendas: Lessons from Project LEAD
Program, United States
“They are not scientists but their connection to cancer is
no less strong”,[5] writes Kana about the Georgetown
Lombardi’s Patient Advocacy Committee (GLBCPAC), a
non-profit organization formed by Ayesha Shajahan-
Haq. “Encouraging researchers, basic or clinical, to work
with advocates is the right step to help in bridging the
gap between cancer research and the community it is
intended to directly impact” says Shajahan-Haq.[5] The
GLBCPAC is made up of 14 breast cancer patient advo-
cates and five of them are formally trained National
Breast Cancer Coalition Project LEAD graduates [5].
Project LEAD is the National Breast Cancer Coali-
tion’s (NBCC) premier science training program for
patient advocates in the United States and has created a
revolution in the world of breast cancer research and
public policy. The courses prepare graduates to engage
in a wide range of local and national forums where
breast cancer decisions are made. Project LEAD gradu-
ates bring an educated consumer perspective and critical
thinking skills to the important issues and controversies
in breast cancer [6].
As a result of NBCC’s work, scientists, government
agencies and private industry have changed the way they
design and implement breast cancer research and pro-
grams. NBCC has created a model for consumer influ-
ence marked by transparency, innovation and a peer
relationship among scientists, researchers, policymakers
and consumers [6] in the United States. In addition, Pro-
ject LEAD International is slowly growing this influence
globally. The respect for and influence of NBCC Project
LEAD graduates is not limited to research science but
also extends to high level political structures. The NBCC
has had tremendous success in influencing United States
national public-policy on breast cancer research. For
example, the Department of Defense (DOD) Breast Can-
cer Research Program (BCRP) was created in 1992 as a
result of the organization’s campaign to increase United
States federal funding for breast cancer research [7]. Stra-
tegic partnership with supportive Congressional leaders
like Senators Tom Harkin (a democrat from Iowa) and
Alfonse D’ Amato (republican from New York) led the
United States Congress to appropriate $210 million in
the DOD research and development budget for breast
cancer peer-reviewed research program administered by
the United States Department of the Army, during the
1993 financial year [7]. As a result of Senator Harkin’s
continued support, NBCC grassroots advocacy, and the
DOD BCRP’s demonstrated success, Congress has
approved funding for breast cancer research annually [7].
It is worth noting that the development of the drug
Herceptin which has saved the lives of many women
with HER-2 positive breast cancer is one of the key suc-
cesses of the DOD BCRP. United States Speaker Nancy
Pelosi’s 2010 NBCC Congressional Awards acceptance
speech when she was presented with the Public Policy
Leadership Award, best capture the high political regard
accorded the patient advocate organization on Capitol
Hill:
“I know the National Breast Cancer Coalition’s number
one legislative priority is access to quality health care
for all. And because of your advocacy, your organiza-
tion, your number one legislative priority is now the
law of the land.” [8]. Already we are seeing progress.
As you know, the media has reported that certain
insurance companies were particularly targeting
women with breast cancer diagnoses for rescission.
But because of your leadership, America largest
insurers acted even sooner than the health insurance
reform bill we passed required to end the shameful
practice of dropping women’s coverage when they get
sick”.[8]We are counting on (the NBCC) to continue
to work with us to educate the American people
about what health care reform means to them” [8].
I know you have come to Capitol Hill to lobby for
increased funding for breast cancer research. We
have been working together on this issue for years. In
the early years, our battle was to make sure the NIH
was directing resources to breast cancer. I remember
when we broke the first $100 million mark for breast
cancer funding. With the help of Jack Murtha,
together we created the Breast Cancer Research Pro-
gram at the Defense Department, which has invested
$2 billion in research since 1993.” [8].
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Between 1992 and 2012, the power of political breast
cancer advocacy resulted in $2.78 billion United States
Congregational appropriation for the DOD Breast Cancer
Research Program and over 6,000 grant awards. The same
success can be achieved in Africa with the right partner-
ship between the government and advocates.
Conclusion
Patient advocates have carved themselves a niche and
earned trust as peers and key partners in research, clini-
cal and policymaking forums. Although the patient
advocacy movement is still relatively young in Africa
compared to Western countries like the United States,
the South African Treatment Action Campaign and its
patient alliance partners showed their mettle in the for-
midable battle to secure equitable access to evidence-
based HIV/AIDS treatment to millions of people who
needed it. Great strides in patient engagement have
been made by South African healthcare policymakers.
The Minister of Health showed a strong commitment to
patient inclusion by appointing three lay persons to his
inaugural Cancer Advisory Committee – which started
its 3-year term in April 2013. A patient has also been
elected to serve as Deputy Chair of the Committee.
There are great lessons and partnerships to be forged
between HIV/AIDS and cancer patient advocates. In
addition, broader synergies and partnerships need to be
fostered among clinicians, researchers and policymakers
to create integrated and context relevant, cost effective
and sustainable healthcare systems in Africa. Lessons
from the United States based NBCC Project LEAD and
the GLBCPAC also serve as great illustrations of the
impact and value that science trained patient advocates
can bring to both the research and policymaking arenas.
Testimonies from clinicians, researchers and high level
public office holders offer evidence of how patient inclu-
sion in key healthcare forums is a public policy, societal
and business imperative. The examples offer lessons for
African countries to emulate.
The author is a a Project LEAD graduate of the NBCC
Project LEAD, a member of the NBCC and Deputy
Chair of the South Africa Minister of Health Cancer
Advisory Committee.
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